Rona R Ramsay

List of Publications by Year
in descending order

138 papers	7,102 citations	57719 44 h-index	60583 81 g-index
140 all docs	140 docs citations	140 times ranked	7169 citing authors

#	Article	IF	Citations
1	A perspective on multiâ€target drug discovery and design for complex diseases. Clinical and Translational Medicine, 2018, 7, 3.	1.7	481
2	Molecular enzymology of carnitine transfer and transport. BBA - Proteins and Proteomics, 2001, 1546, 21-43.	2.1	315
3	Identification of 4-Substituted 1,2,3-Triazoles as Novel Oxazolidinone Antibacterial Agents with Reduced Activity against Monoamine Oxidase A. Journal of Medicinal Chemistry, 2005, 48, 499-506.	2.9	282
4	Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochemical and Biophysical Research Communications, 1986, 134, 743-748.	1.0	260
5	Biochemical Events in the Development of Parkinsonism Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine. Journal of Neurochemistry, 1987, 49, 1-8.	2.1	254
6	Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochemical and Biophysical Research Communications, 1986, 135, 269-275.	1.0	249
7	Inhibition of Monoamine Oxidase A by Î²-Carboline Derivatives. Archives of Biochemistry and Biophysics, 1997, 337, 137-142.	1.4	234
8	Interaction of 1-Methyl-4-Phenylpyridinium Ion (MPP+) and Its Analogs with the Rotenone/Piericidin Binding Site of NADH Dehydrogenase. Journal of Neurochemistry, 1991, 56, 1184-1190.	2.1	213
9	Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. British Journal of Pharmacology, 2007, 152, 946-951.	2.7	208
10	Mechanism of the neurotoxicity of MPTP. FEBS Letters, 1990, 274, 1-8.	1.3	177
11	Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sciences, 1986, 39, 581-588.	2.0	165
12	The mechanism of fatty acid uptake by heart mitochondria: An acylcarnitine-carnitine exchange. FEBS Letters, 1975, 54, 21-25.	1.3	162
13	Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs. Molecules, 2017, 22, 1192.	1.7	156
14	Carnitine acyltransferases and their influence on CoA pools in health and disease. Molecular Aspects of Medicine, 2004, 25, 475-493.	2.7	122
15	Carnitine, mitochondrial function and therapyâ˜†. Advanced Drug Delivery Reviews, 2009, 61, 1353-1362.	6.6	120
16	The Carnitine Acyltransferases and Their Role in Modulating Acyl-CoA Pools. Archives of Biochemistry and Biophysics, 1993, 302, 307-314.	1.4	111
17	Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease. Frontiers in Neuroscience, 2016, 10, 205.	1.4	111
18	The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Archives of Biochemistry and Biophysics, 1987, 259, 645-649.	1.4	106

#	Article	IF	Citations
19	Monoamine Oxidases: The Biochemistry of the Proteins As Targets in Medicinal Chemistry and Drug Discovery. Current Topics in Medicinal Chemistry, 2012, 12, 2189-2209.	1.0	97
20	In vitro effects of acetaminophen metabolites and analogs on the respiration of mouse liver mitochondria. Archives of Biochemistry and Biophysics, 1989, 273, 449-457.	1.4	89
21	Evidence that the blockade of mitochondrial respiration by the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) involves binding at the same site as the respiratory inhibitor, rotenone. Biochemical and Biophysical Research Communications, 1990, 169, 123-128.	1.0	86
22	Multitargetâ€Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H₃R Antagonism for Neurodegenerative Diseases. Angewandte Chemie - International Edition, 2017, 56, 12765-12769.	7.2	83
23	Mechanism of the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP)+, the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicology, 1988, 49, 17-23.	2.0	82
24	Relation of superoxide generation and lipid peroxidation to the inhibition of NADH-Q oxidoreductase by rotenone, piericidin A, and MPP+. Biochemical and Biophysical Research Communications, 1992, 189, 47-52.	1.0	78
25	The carnitine acyltransferases: modulators of acyl-CoA-dependent reactions. Biochemical Society Transactions, 2000, 28, 182-186.	1.6	76
26	One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug. Frontiers in Neuroscience, 2016, 10, 177.	1.4	75
27	Substrate-specific enhancement of the oxidative half-reaction of monoamine oxidase. Biochemistry, 1993, 32, 2137-2143.	1.2	71
28	The reaction sites of rotenone and ubiquinone with mitochondrial NADH dehydrogenase. Biochimica Et Biophysica Acta - Bioenergetics, 1994, 1187, 198-202.	0.5	71
29	Molecular aspects of monoamine oxidase B. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 69, 81-89.	2.5	70
30	Monoamine oxidases: old friends hold many surprises. FASEB Journal, 1995, 9, 605-610.	0.2	69
31	Kinetics, mechanism, and inhibition of monoamine oxidase. Journal of Neural Transmission, 2018, 125, 1659-1683.	1.4	65
32	Inhibitor Design for Monoamine Oxidases. Current Pharmaceutical Design, 2013, 19, 2529-2539.	0.9	63
33	Oxidation of Analogs of l-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine by Monoamine Oxidases A and B and the Inhibition of Monoamine Oxidases by the Oxidation Products. Journal of Neurochemistry, 1989, 53, 1837-1842.	2.1	61
34	Structural dependence of the inhibition of mitochondrial respiration and of NADH oxidase by 1-methyl-4-phenylpyridinium (MPP+) analogs and their energized accumulation by mitochondria.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 9168-9172.	3.3	60
35	ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy. Frontiers in Neuroscience, 2016, 10, 294.	1.4	58
36	The Effects of Temperature and Some Inhibitors an the Carnitine Exchange System of Heart Mitochondria. FEBS Journal, 1976, 69, 299-303.	0.2	57

#	Article	IF	Citations
37	<i>N</i>-Methyl-<i>N</i>-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1<i>H</i>-indol-2-yl)methyl)prop-2-yn-1-amine, a New Cholinesterase and Monoamine Oxidase Dual Inhibitor. Journal of Medicinal Chemistry, 2014, 57, 10455-10463.	2.9	56
38	Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration. Frontiers in Neuroscience, 2016, 10, 375.	1.4	55
39	Kinetic mechanism of monoamine oxidase A. Biochemistry, 1991, 30, 4624-4629.	1.2	52
40	Regulation of the longâ€chain carnitine acyltransferases. FASEB Journal, 1993, 7, 1039-1044.	0.2	52
41	Dietary inhibitors of monoamine oxidase A. Journal of Neural Transmission, 2011, 118, 1031-1041.	1.4	48
42	Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1104-1110.	1.1	48
43	Dramatic Species Differences in the Susceptibility of Monoamine Oxidase B to a Group of Powerful Inhibitors. Biochemical and Biophysical Research Communications, 1995, 206, 556-562.	1.0	47
44	Reaction site of carboxanilides and of thenoyltrifluoroacetone in complex II.. Proceedings of the National Academy of Sciences of the United States of America, 1981, 78, 825-828.	3.3	46
45	On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B. Pharmacological Research, 2010, 62, 475-488.	3.1	46
46	A Stable Tyrosyl Radical in Monoamine Oxidase A. Journal of Biological Chemistry, 2005, 280, 4627-4631.	1.6	45
47	Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimerâ€™s disease treatment. Bioorganic and Medicinal Chemistry, 2017, 25, 1143-1152.	1.4	45
48	Characterization of the Covalently Bound Anionic Flavin Radical in Monoamine Oxidase A by Electron Paramagnetic Resonance. Journal of the American Chemical Society, 2007, 129, 16091-16097.	6.6	44
49	Mutation of surface cysteine 374 to alanine in monoamine oxidase A alters substrate turnover and inactivation by cyclopropylamines. Bioorganic and Medicinal Chemistry, 2005, 13, 3487-3495.	1.4	43
50	Variations in activity and inhibition with pH: the protonated amine is the substrate for monoamine oxidase, but uncharged inhibitors bind better. Journal of Neural Transmission, 2007, 114, 707-712.	1.4	43
51	The Role of the Carnitine System in Peroxisomal Fatty Acid Oxidation. American Journal of the Medical Sciences, 1999, 318, 28.	0.4	43
52	Inhibition of NADH oxidation by pyridine derivatives. Biochemical and Biophysical Research Communications, 1987, 146, 53-60.	1.0	42
53	Stopped-flow studies on the mechanism of oxidation of N-methyl-4-phenyltetrahydropyridine by bovine liver monoamine oxidase B. Biochemistry, 1987, 26, 3045-3050.	1.2	42
54	Enhancement by tetraphenylboron of the interaction of the 1-methyl-4-phenylpyridinium ion (MPP+) with mitochondria. Biochemical and Biophysical Research Communications, 1989, 159, 983-990.	1.0	41

#	Article	IF	Citations
55	Inhibitor Probes of the Quinone Binding Sites of Mammalian Complex II and Escherichia coli Fumarate Reductase. Journal of Biological Chemistry, 1996, 271, 21020-21024.	1.6	39
56	2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 1388-1395.	1.4	39
57	A snapshot of carnitine acetyltransferase. Trends in Biochemical Sciences, 2003, 28, 343-346.	3.7	37
58	Studies on the Characterization of the Inhibitory Mechanism of 4â€²â€Alkylated 1â€Methylâ€4â€Phenylpyridinium and Phenylpyridine Analogues in Mitochondria and Electron Transport Particles. Journal of Neurochemistry, 1994, 63, 655-661.	2.1	36
59	Monoamine Oxidases: to Inhibit or Not to Inhibit. Mini-Reviews in Medicinal Chemistry, 2003, 3, 129-136.	1.1	36
60	III. Bioactivation of MPTP: Reactive metabolites and possible biochemical sequelae. Life Sciences, 1987, 40, 713-719.	2.0	35
61	Design, Synthesis and in vitro Evaluation of Indolotacrine Analogues as Multitargetâ€Directed Ligands for the Treatment of Alzheimer's Disease. ChemMedChem, 2016, 11, 1264-1269.	1.6	35
62	Inhibition of complex I by hydrophobic analogues of N-methyl-4-phenylpyridinium (MPP+) and the use of an ion-selective electrode to measure their accumulation by mitochondria and electron-transport particles. Biochemical Journal, 1995, 306, 359-365.	1.7	34
63	Deficiencies of NADH and succinate dehydrogenases in degenerative diseases and myopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1995, 1271, 211-219.	1.8	34
64	Relationship of the oxidation state of the iron sulfur cluster of aconitase to activity and substrate binding. Biochemistry, 1981, 20, 7476-7482.	1.2	33
65	<i>cis</i>â€cyclopropylamines as mechanismâ€based inhibitors of monoamine oxidases. FEBS Journal, 2015, 282, 3190-3198.	2.2	31
66	Malonyl-CoA inhibition of peroxisomal carnitine octanoyltransferase. Biochemical Journal, 1992, 286, 637-640.	1.7	30
67	Palmitoyl-L-carnitine, a metabolic intermediate of the fatty acid incorporation pathway in erythrocyte membrane phospholipids. Biochemical and Biophysical Research Communications, 1990, 173, 212-217.	1.0	28
68	Live cell interactome of the human voltage dependent anion channel 3 (VDAC3) revealed in HeLa cells by affinity purification tag technique. Molecular BioSystems, 2014, 10, 2134-2145.	2.9	28
69	Tacrine-allyl/propargylcysteineâ€"benzothiazole trihybrids as potential anti-Alzheimer's drug candidates. RSC Advances, 2016, 6, 53519-53532.	1.7	27
70	Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B. Scientific Reports, 2017, 7, 40541.	1.6	27
71	Characteristics of L-carnitine transport by lactating rat mammary tissue. Lipids and Lipid Metabolism, 1998, 1393, 49-56.	2.6	24
72	Electron carriers and energy conservation in mitochondrial respiration. ChemTexts, 2019, 5, 1.	1.0	24

#	Article	IF	Citations
73	Orientation of oxazolidinones in the active site of monoamine oxidase. Biochemical Pharmacology, 2005, 70, 407-416.	2.0	23
74	Interactions of imidazoline ligands with the active site of purified monoamine oxidase A. FEBS Journal, 2007, 274, 1567-1575.	2.2	23
75	Syntheses, Structures, and Enzymic Evaluations of Conformationally Constrained, Analog Inhibitors of Carnitine Acetyltransferase: (2R,6R)-, (2S,6S)-, (2R,6S)-, and (2S,6R)-6-(Carboxylatomethyl)-2-(hydroxymethyl)-2,4,4-trimethylmorpholinium. Journal of Organic Chemistry, 1995, 60, 6688-6695.	1.7	22
76	Monoamine Oxidase Contains a Redox-active Disulfide. Journal of Biological Chemistry, 1998, 273, 14074-14076.	1.6	22
77	Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochimica Et Biophysica Acta - General Subjects, 2004, 1672, 60-66.	1.1	22
78	An improved approach to steady-state analysis of monoamine oxidases. Journal of Neural Transmission, 2011, 118, 1003-1019.	1.4	22
79	Comparative Analysis of the Neurochemical Profile and MAO Inhibition Properties of <i>N</i>-(Furan-2-ylmethyl)-<i>N</i>-methylprop-2-yn-1-amine. ACS Chemical Neuroscience, 2017, 8, 1026-1035.	1.7	22
80	A case of carnitine palmitoyltransferase II deficiency in human skeletal muscle. FEBS Letters, 1988, 241, 126-130.	1.3	21
81	Inhibitors alter the spectrum and redox properties of monoamine oxidase A. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2002, 1601, 178-184.	1.1	21
82	Evidence for a Cyanine Link Between Propargylamine Drugs and Monoamine Oxidase Clarifies the Inactivation Mechanism. Frontiers in Chemistry, 2018, 6, 169.	1.8	21
83	(+)-Hemipalmitoylcarnitinium strongly inhibits carnitine palmitoyltransferase-I in intact mitochondria. Journal of Medicinal Chemistry, 1993, 36, 237-242.	2.9	18
84	Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure. Biochemical Pharmacology, 2003, 65, 1867-1874.	2.0	18
85	Regulation of Carnitine Acyltransferase Synthesis in Lean and Obese Zucker Rats by Dehydroepiandrosterone and Clofibrate. Journal of Nutrition, 1991, 121, 525-531.	1.3	16
86	Secondary Structure of Monoamine Oxidase by FTIR Spectroscopy. Biochemical and Biophysical Research Communications, 1995, 208, 773-778.	1.0	16
87	Substrates but Not Inhibitors Alter the Redox Potentials of Monoamine Oxidases. Antioxidants and Redox Signaling, 2001, 3, 723-729.	2.5	16
88	Exploring the structural basis of the selective inhibition of monoamine oxidase A by dicarbonitrile aminoheterocycles: Role of Asn181 and Ile335 validated by spectroscopic and computational studies. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 389-397.	1.1	16
89	Predicting targets of compounds against neurological diseases using cheminformatic methodology. Journal of Computer-Aided Molecular Design, 2015, 29, 183-198.	1.3	16
90	Chapter 6 NADH-ubiquinone oxidoreductase. New Comprehensive Biochemistry, 1992, 23, 145-162.	0.1	15

#	Article	IF	Citations
91	The Role of the Carnitine System in Peroxisomal Fatty Acid Oxidation. American Journal of the Medical Sciences, 1999, 318, 28-35.	0.4	14
92	The interaction of monoamine oxidases with tertiary amines. Biochemical Society Transactions, 1991, 19, 211-215.	1.6	13
93	Syntheses, structures, and enzymatic evaluations of hemiacylcarnitiniums, a new class of carnitine acyltransferase inhibitors. Journal of Organic Chemistry, 1992, 57, 3426-3431.	1.7	13
94	Chapter 3 Redox properties of the flavin cofactor of monoamine oxidases A and B and their relationship to the kinetic mechanism. Progress in Brain Research, 1995, 106, 33-39.	0.9	13
95	Computational Comparison of Imidazoline Association with the I2 Binding Site in Human Monoamine Oxidases. Journal of Chemical Information and Modeling, 2014, 54, 1200-1207.	2.5	13
96	Neuroprotective actions of leptin facilitated through balancing mitochondrial morphology and improving mitochondrial function. Journal of Neurochemistry, 2020, 155, 191-206.	2.1	13
97	The Role of Carnitine, the Carnitine Acyltransferases and the Carnitine-Exchange System. Biochemical Society Transactions, 1978, 6, 72-76.	1.6	12
98	The kinetic mechanisms of monoamine oxidases A and B. Biochemical Society Transactions, 1991, 19, 219-223.	1.6	12
99	Reactivation of NADH Dehydrogenase (Complex I) Inhibited by 1-Methyl-4-(4'-Alkylphenyl)pyridinium Analogues: A Clue to the Nature of the Inhibition Site. Journal of Neurochemistry, 1993, 61, 1546-1548.	2.1	12
100	Exchange of the Endogenous Carnitine of Ox Heart Mitochondria with External Carnitine and its Possible Relevance to the Mechanism of Fatty-Acyl Transport into Mitochondria. Biochemical Society Transactions, 1974, 2, 1285-1286.	1.6	11
101	Neurobiology and neuropharmacology of monoaminergic systems. Progress in Neurobiology, 2017, 151, 1-3.	2.8	11
102	Oxidation of tetrahydrostilbazole by monoamine oxidase A demonstrates the effect of alternate pathways in the kinetic mechanism. Biochemistry, 1993, 32, 9025-9030.	1.2	10
103	Parameters for Irreversible Inactivation of Monoamine Oxidase. Molecules, 2020, 25, 5908.	1.7	10
104	INHIBITORS OF CARNITINE TRANSPORT AND METABOLISM. , 1980, , 207-218.		10
105	Inhibition of NADH oxidation by 1-methyl-4-phenylpyridinium analogs as the basis for the prediction of the inhibitory potency of novel compounds. Journal of Biochemical Toxicology, 1996, 11, 33-43.	0.5	9
106	Active sites residues of beef liver carnitine octanoyltransferase (COT) and carnitine palmitoyltransferase (CPT-II). Biochemical Journal, 1998, 330, 1029-1036.	1.7	9
107	TCP-FA4: A derivative of tranylcypromine showing improved bloodâ€“brain permeability. Biochemical Pharmacology, 2009, 78, 1412-1417.	2.0	9
108	Substrate regulation of monoamine oxidases. Journal of Neural Transmission Supplementum, 1998, 52, 139-147.	0.5	9

#	Article	IF	Citations
109	Selective Modulation of Carnitine Long-chain Acyltransferase Activities. Advances in Experimental Medicine and Biology, 2002, , 103-109.	0.8	8
110	Editorial: Structure-Based Drug Design for Diagnosis and Treatment of Neurological Diseases. Frontiers in Pharmacology, 2017, 8, 13.	1.6	8
111	Synthesis, biological evaluation, and molecular modeling of nitrileâ€containing compounds: Exploring multiple activities as antiâ€Alzheimer agents. Drug Development Research, 2020, 81, 215-231.	1.4	8
112	Evidence that the activation of aconitase involves a conformational change. Biochemical Journal, 1982, 203, 327-330.	1.7	7
113	A new class of powerful inhibitors of monoamine oxidase A. Biochemical and Biophysical Research Communications, 1990, 172, 1338-1341.	1.0	5
114	Expression of a sodium-dependent L-carnitine transporter in lactating rat mammary tissue. Biochemical Society Transactions, 1998, 26, S96-S96.	1.6	5
115	Design, synthesis, molecular modelling and<i>in vitro</i>screening of monoamine oxidase inhibitory activities of novel quinazolyl hydrazine derivatives. Royal Society Open Science, 2020, 7, 200050.	1.1	5
116	Questions in the Chemical Enzymology of MAO. Chemistry, 2021, 3, 959-978.	0.9	5
117	Iron-Sulfur Clusters in Mitochondrial Enzymes. , 1985, , 301-332.		5
118	Evaluation of (2S,4S)/(2R,4R) and (2S,4R)/(2R,4S) 6,6-N,N-dimethyl-2-methyl-2-oxo-1,3-dioxa-4-hexadecyl-6,aza-2-phosphacyclooctane bromide as inhibitors for protein kinase C, carnitine octanoyltransferase, and carnitine palmitoyltransferase. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 883-886.	1.0	4
119	Difference spectra for inhibitor binding to monoamine oxidases. Biochemical Society Transactions, 1995, 23, 457S-457S.	1.6	4
120	Interactions of D-amphetamine with the active site of monoamine oxidase-A. Inflammopharmacology, 2003, 11, 127-133.	1.9	4
121	Purification and properties of an easily solubilized l-carnitine palmitoyltransferase from beef liver mitochondria. Biochemical Society Transactions, 1986, 14, 698-698.	1.6	3
122	Carnitine palmitoyltransferase and acyl-coA binding protein: two more players in the membrane phospholipid fatty acid turnover of human red cells?. Biochemical Journal, 1997, 325, 811-814.	1.7	3
123	Biochemical Reactions Leading to Parkinsonian Symptoms Elicited by MPTP. Advances in Behavioral Biology, 1990, , 219-225.	0.2	3
124	Observations on the mechanism of activation of aconitase. Biochemical Society Transactions, 1982, 10, 538-539.	1.6	2
125	Aggregation of submitochondrial particles by heparin and its application to the study of carnitine transport. Biochemical Journal, 1986, 235, 297-299.	1.7	2
126	Carnitine analogues and carnitine palmitoyltransferases. Biochemical Society Transactions, 1990, 18, 604-605.	1.6	2

#	Article	IF	Citations
127	The active site histidine of carnitine acyltransferases. Biochemical Society Transactions, 1995, 23, 490S-490S.	1.6	2
128	The G553M Mutant of Peroxisomal Carnitine Octanoyltransferase Catalyses Acetyl Transfer and Acetyl-CoA Hydrolysis. Monatshefte FÃ¼r Chemie, 2005, 136, 1341-1347.	0.9	2
129	MAO and aggression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 69, 79-80.	2.5	2
130	Updating neuropathology and neuropharmacology of monoaminergic systems. British Journal of Pharmacology, 2016, 173, 2065-2068.	2.7	2
131	Multipotente Liganden mit kombinierter Cholinesteraseâ€•und Monoaminooxidaseâ€•Inhibition sowie Histaminâ€H 3 Râ€Antagonismus bei neurodegenerativen Erkrankungen. Angewandte Chemie, 2017, 129, 12939-12943.	1.6	2
132	Selective Inhibition of Monoamine Oxidase B by Aminoethyl Substituted Benzyl Ethers. Journal of Enzyme Inhibition and Medicinal Chemistry, 1999, 15, 11-21.	0.5	1
133	Interdisciplinary Chemical Approaches for Neuropathology. CNS Neuroscience and Therapeutics, 2014, 20, 571-573.	1.9	1
134	Monoamine Oxidases: The Biochemistry of the Proteins As Targets in Medicinal Chemistry and Drug Discovery. Current Topics in Medicinal Chemistry, 2013, 12, 2189-2209.	1.0	1
135	Biochemistry Of The Neurotoxic Action Of MPTP And What It May Teach Us About The Etiology Of Idiopathic Parkinsonism. , 1988, , 101-111.		1
136	Substrate-specific enhancement of the oxidative half-reaction of monoamine oxidase. [Erratum to document cited in CA118(13):119713e]. Biochemistry, 1993, 32, 5490-5490.	1.2	0
137	Enyzmes | Monoamine Oxidase (EC 1.4.3.4). , 2021, , 249-260.		0
138	Molecular Aspects of the Activity and Inhibition of the FAD-Containing Monoamine Oxidases. , 2019, , 397-425.		0